Real ChatGPT answer · index seed9xvFUKyZduEcompleteHealth and wellness · supplements and vitaminsinformational
What is the current consensus on flushing versus non-flushing niacin formulations for controlling high cholesterol without causing liver strain?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What is the current consensus on flushing versus non-flushing niacin formulations for controlling high cholesterol without causing liver strain?
3 real searches · 1 real-search pass
2026 guideline consensus niacin dyslipidemia not recommended cardiovascular outcomes liver toxicity formulations immediate release sustained release extended releaseGoogle ↗
OBSERVEDConsequence
NIH LiverTox niacin sustained release immediate release hepatotoxicity formulationGoogle ↗
OBSERVEDConsequence
FDA niacin extended release label liver function monitoring sustained release hepatotoxicityGoogle ↗
OBSERVEDConsequence
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
ChatGPT real searches (3)
Classes come from the query-classifier (a local Laya model). 3 of 3 calls are low-confidence (under 50%) — hover a query in the table to see its confidence.
Searches and sources
ChatGPT3 real searches · gpt-6
2026 guideline consensus niacin dyslipidemia not recommended cardiovascular outcomes liver toxicity formulations immediate release sustained release extended release Google ↗
NIH LiverTox niacin sustained release immediate release hepatotoxicity formulation Google ↗
FDA niacin extended release label liver function monitoring sustained release hepatotoxicity Google ↗
- Niacin - LiverTox · ncbi.nlm.nih.gov
- Triglyceride Lowering Drugs - Endotext · ncbi.nlm.nih.gov
- Niacin · ods.od.nih.gov
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · ahajournals.org
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · ahajournals.org
- These highlights do not include all the information needed to use NIACIN EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for NIACIN EXTENDED-RELEASE TABLETS. NIACIN extended-release tablets USP, film coated, for oral useInitial U.S. Approval: 1997 · dailymed.nlm.nih.gov
- Niacin Extended-Release Tablets These highlights do not include all the information needed to use niacin extended-release tablets safely and effectively. See full prescribing information for niacin extended-release tablets. NIACIN extended-release tablets, film-coated, for oral use. Initial U.S. Approval: 1997 · dailymed.nlm.nih.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2026 guideline consensus niacin dyslipidemia not recommended cardiovascular outcomes liver toxicity formulations immediate release sustained release extended release OBSERVED | Google ↗ AI Mode ↗ | — | Consequence | — | — | 1x of 1 | |
NIH LiverTox niacin sustained release immediate release hepatotoxicity formulation OBSERVED | Google ↗ AI Mode ↗ | — | Consequence | — | — | 1x of 1 | |
FDA niacin extended release label liver function monitoring sustained release hepatotoxicity OBSERVED | Google ↗ AI Mode ↗ | — | Consequence | — | — | 1x of 1 |